Evidence map›Paper›PMID 32979176›Full record

ArticleCardiovascular drugs and therapy2020

Confirmation of the Cardioprotective Effect of MitoGamide in the Diabetic Heart.

Min Park, Takanori Nishimura, Carlos D Baeza-Garza, Stuart T Caldwell, Pamela Boon Li Pun, Hiran A Prag, Tim Young, Olga Sauchanka, Angela Logan, Marleen Forkink and 15 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Guidelines for diet-induced models of cardiometabolic syndrome.American journal of physiology. Heart and circulatory physiology · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. The Role of Mitochondrial Abnormalities in Diabetic Cardiomyopathy.International journal of molecular sciences · 2022
    Review
  7. Guidelines on models of diabetic heart disease.American journal of physiology. Heart and circulatory physiology · 2022
    Review
  8. CaPflugers Archiv : European journal of physiology · 2022
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 6 countries.

Min ParkDepartment of Medicine, University of Cambridge, Cambridge, UK.
Takanori NishimuraMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
Carlos D Baeza-GarzaWestCHEM School of Chemistry, University of Glasgow, Glasgow, UK.
Stuart T CaldwellWestCHEM School of Chemistry, University of Glasgow, Glasgow, UK.
Pamela Boon Li PunMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
Hiran A PragMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
Tim YoungDepartment of Medicine, University of Cambridge, Cambridge, UK.
Olga SauchankaDepartment of Medicine, University of Cambridge, Cambridge, UK.
Angela LoganMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
Marleen ForkinkDepartment of Medicine, University of Cambridge, Cambridge, UK.
Anja V GruszczykMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
Tracy A PrimeMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
Sabine ArndtMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
Alba NaudiDepartment Of Experimental Medicine, University of Lleida, Lleida Institute for Biomedical Research, Lleida, Spain.
Reinald PamplonaDepartment Of Experimental Medicine, University of Lleida, Lleida Institute for Biomedical Research, Lleida, Spain.
Melinda T CoughlanDepartment of Diabetes, Monash University, Melbourne, Australia.
Mitchel TateDepartment of Diabetes, Monash University, Melbourne, Australia.
Rebecca H RitchieDepartment of Diabetes, Monash University, Melbourne, Australia.
Federico CaicciDepartment of Biology, University of Padova, Padua, Italy.
Nina KaludercicNeuroscience Institute, National Research Council of Italy (CNR), Pisa, Italy.
Fabio Di LisaDepartment of Biomedical Sciences, University of Padova, Padua, Italy.
Robin A J SmithDepartment of Chemistry, University of Otago, Otago, New Zealand.
Richard C HartleyWestCHEM School of Chemistry, University of Glasgow, Glasgow, UK.
Michael P MurphyDepartment of Medicine, University of Cambridge, Cambridge, UK.
Thomas KriegDepartment of Medicine, University of Cambridge, Cambridge, UK. tk382@medschl.cam.ac.uk.ORCID 0000-0002-5192-580X
University of Cambridge · GBUniversity of Glasgow · GBBaker Heart and Diabetes Institute · AUUniversitat de Lleida · ESUniversity of Padua · ITMonash University · AUNeuroscience Institute · ITUniversity of Otago · NZ

Funding

British Heart Foundation PG/15/84/31670Medical Research Council MC_U105663142Wellcome Trust 110158/Z/15/Z
6 · The paper itself

Abstract

purposeHFpEF (heart failure with preserved ejection fraction) is a major consequence of diabetic cardiomyopathy with no effective treatments. Here, we have characterized Akita mice as a preclinical model of HFpEF and used it to confirm the therapeutic efficacy of the mitochondria-targeted dicarbonyl scavenger, MitoGamide. METHODS AND

resultsA longitudinal echocardiographic analysis confirmed that Akita mice develop diastolic dysfunction with reduced E peak velocity, E/A ratio and extended isovolumetric relaxation time (IVRT), while the systolic function remains comparable with wild-type mice. The myocardium of Akita mice had a decreased ATP/ADP ratio, elevated mitochondrial oxidative stress and increased organelle density, compared with that of wild-type mice. MitoGamide, a mitochondria-targeted 1,2-dicarbonyl scavenger, exhibited good stability in vivo, uptake into cells and mitochondria and reactivity with dicarbonyls. Treatment of Akita mice with MitoGamide for 12 weeks significantly improved the E/A ratio compared with the vehicle-treated group.

conclusionOur work confirms that the Akita mouse model of diabetes replicates key clinical features of diabetic HFpEF, including cardiac and mitochondrial dysfunction. Furthermore, in this independent study, MitoGamide treatment improved diastolic function in Akita mice.

Indexed as

AnimalsBenzamidesCardiovascular AgentsDiabetic CardiomyopathiesDisease Models, AnimalGlycation End Products, AdvancedHeart FailureMaleMice, Inbred C57BLMice, Mutant StrainsMitochondria, HeartStroke VolumeVentricular Dysfunction, LeftVentricular Function, LeftBenzamidesCardiovascular AgentsGlycation End Products, AdvancedMitoGamideAdvanced glycation endproducts (AGE)Akita miceDiabetesHeart failure with preserved ejection fraction (HFpEF)Mitochondria

Identifiers

PMID32979176
PMCPMC7674384
OpenAlexW3088382863

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.